VIDO-InterVac COVID-19 vaccine to start toxicology studies

There are many headlines about the global effort to develop a vaccine for COVID-19. Institutions from all over the world are applying different technologies to reach this goal, and here in Canada, VIDO-InterVac is leading a major part of Canada’s response.

Our work to develop and advance a COVID-19 vaccine candidate has progressed rapidly throughout the summer. Most recently, we manufactured the vaccine antigen – a key part of our prototype vaccine. The vaccine will be used in toxicology studies this month to demonstrate the safety of our made in Canada vaccine candidate. Success in these toxicology trials is a critical milestone in obtaining permission from Health Canada to move to the next step – human clinical trials.

Working with the Canadian Center for Vaccinology in Halifax, Nova Scotia, we have developed plan to outline how human clinical trials will be conducted. Participant enrollment will begin immediately upon receiving the necessary approvals from Health Canada, and our goal is to start Phase I clinical trials in Q4 2020.

In addition, we have engaged with more than 60 organizations globally to conduct pre-clinical studies for novel vaccines, antivirals, and therapeutics against COVID-19. The ultimate goal is to develop a safe and scalable solution for this pandemic as quickly as possible, realizing our vision of protecting Canada and the world from infectious diseases.

To find out more about VIDO-InterVac’s work on a COVID-19 vaccine, please contact Trenna Brusky at info@vido.org with your questions.